MSH|^~\&|LAB|YRC|||202001201438||ORU^R01|4149738|D|2.3|||AL|NE
PID|1||YC00000503|YC503|LABTEST^LABRADOR^||19470205|M||||||||||YX001001/17|9876428123
OBR|1|38071^LAB|00028706^1601:C00013R^LAB^160120:C13^38071|500.6095^LIPID^Lipids^^^24331-1||202001161635|202001161635|||||||202001161635||||||||||LAB|F||||
OBX|1|ST|500.6300^CHOL R^Cholesterol^^14647-2^14647-2|1|4.0^^Y|mmol/L|2.0-5.2|N||A^S|F|||202001201438
OBX|2|ST|500.6400^TRIG R^Triglycerides^^14927-8^14927-8|1|2.3^^Y|mmol/L|<2.3|H||A^S|F|||202001201438
OBX|3|ST|500.6500^HDL^HDL Cholesterol^^14646-4^14646-4|1|2.9^^Y|mmol/L|>0.9|N||A^S|F|||202001201438
OBX|4|ST|500.6600^LDL^LDL Cholesterol^^39469-2^39469-2|1|< 0.1^^Y|mmol/L|1.5-3.4|L||A^S|F|||202001201438
NTE|1||The optimal LDL cholesterol for intermediate and high risk
NTE|2||individuals is less than 2.1 mmol/L. If triglycerides are
NTE|3||greater than 1.4 mmol/L, consider monitoring of alternate
NTE|4||lipid targets nonHDL cholesterol or apoB. For low risk
NTE|5||individuals with LDL cholesterol greater than 4.9 mmol/L,
NTE|6||target a reduction of LDL cholesterol of at least 50
NTE|7||percent. See Can J Cardiol 2013 vol 29 pgs 151 to 167.
OBX|5|ST|500.6670^NONHDL^Non-HDL Cholesterol^^70204-3^70204-3|1|1.1^^Y|mmol/L|<4.3|N||A^S|F|||202001201438
NTE|1||Non HDL-cholesterol is calculated from total cholesterol and
NTE|2||HDL-C and is not affected by the fasting status of the
NTE|3||patient. The optimal non HDL-cholesterol level for
NTE|4||intermediate and high risk individuals is less than 2.7
NTE|5||mmol/L. See Can J Cardiol 2013 vol 29 pgs 151 to 167.
OBX|6|ST|500.6760^FASTTIME^Fasting Hours^^55420-4^55420-4|1|11^^N|hr||N||A^S|F|||202001161635